- Home
- HG vs BHVN Comparison
HG vs BHVN Comparison
Compare HG & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | BHVN |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | HG | BHVN |
|---|---|---|
| Price | $34.25 | $13.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 17 |
| Target Price | ★ $38.57 | $21.27 |
| AVG Volume (30 Days) | 360.9K | ★ 2.8M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.86% | N/A |
| EPS Growth | ★ 51.23 | 26.08 |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $2,905,524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | $12.36 | ★ N/A |
| Revenue Growth | ★ 24.70 | N/A |
| 52 Week Low | $22.66 | $7.48 |
| 52 Week High | $37.31 | $18.57 |
Technical Indicators
Market Signals| Indicator | HG | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 44.99 |
| Support Level | $34.26 | $8.75 |
| Resistance Level | $36.43 | $15.27 |
| Average True Range (ATR) | 0.74 | 0.87 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 57.62 | 38.98 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.